Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922312 | 0.83 | CNR1 (0.41) | CNR1 | |
| SCHEMBL4915215 | 0.82 | CNR1 (0.41) | CNR1CXCR3 | |
| SCHEMBL4896075 | 0.77 | CNR1 (0.48) | CNR1 | |
| SCHEMBL4915199 | 0.77 | CNR1 (0.58) | CNR1 | |
| SCHEMBL4902404 | 0.75 | CNR1 (0.47) | CNR1 | |
| SCHEMBL4923174 | 0.73 | CNR1 (0.42) | CNR1CXCR3 | |
| SCHEMBL4637589 | 0.71 | CNR1 (0.69) | CNR1 | |
| SCHEMBL4918897 | 0.70 | CNR1 (0.47) | CNR1 | |
| SCHEMBL4922294 | 0.69 | CNR1 (0.49) | CNR1 | |
| SCHEMBL4918735 | 0.69 | CNR1 (0.40) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| EP-1833802-A2 | 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006067428-A2 | 1, 2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1833802-A2 | 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006067428-A2 | 1, 2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319019-A1 | Therapeutic Agents | SDHA, GPR119, ABAT | CNR1 393/4885CXCR3 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.